Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
- MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company's PhenoCycler®-Fusion and the PhenoImager® HT platforms.
- 05/06/2024
|
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
- MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China's National Medical Products Administration (NMPA) to support next generation pathology clinical workflows.
- 05/02/2024
|
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
- MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 04/22/2024
|
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
- MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode™ Signature Panels and preliminary data from the Thermo Fisher ViewRNA assays on Akoya's platforms.
- 04/05/2024
|
Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider
- WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that it has been named as a qualified contract research organization (CRO) of Akoya Biosciences (Nasdaq: AKYA; “Akoya”). By combining Akoya's single-cell imaging solutions with BostonGene's unparalleled expertise in spatial proteomics sample processing and analysis, researchers will gain unprecedented access to the intricate landscape of cellular biology, paving.
- 03/19/2024
|
Akoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call Transcript
- Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley John Sourbeer - UBS Mark Massaro - BTIG Rachel Vatnsdal - JP Morgan Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Fourth Quarter 2023 Earnings Conference Call.
- 03/04/2024
|
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
- Akoya Biosciences (AKYA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.50 per share a year ago.
- 03/04/2024
|
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
- Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024
- 03/04/2024
|
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
- MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 02/08/2024
|
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
- Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 02/07/2024
|
Akoya Biosciences' Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
- PhenoCycler®-Fusion system selected as the Centre's platform technology for advanced spatial biology studies PhenoCycler®-Fusion system selected as the Centre's platform technology for advanced spatial biology studies
- 01/18/2024
|
Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D.
- Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya's spatial biology solutions Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya's spatial biology solutions
- 01/10/2024
|
5 Small-Cap Stocks to Play the January Effect
- Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
- 01/08/2024
|
Best Momentum Stocks to Buy for January 8th
- AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
- 01/08/2024
|
New Strong Buy Stocks for January 8th
- TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
- 01/08/2024
|
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
- MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023 cash, cash equivalents, and restricted cash balance, which remain subject to quarter end closing adjustments and are also unaudited.
- 01/07/2024
|
Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform
- MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities
- 01/07/2024
|
How Akoya Biosciences (AKYA) Stock Stands Out in a Strong Industry
- Akoya Biosciences (AKYA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
- 01/05/2024
|
How Much Upside is Left in Akoya (AKYA)? Wall Street Analysts Think 86%
- The average of price targets set by Wall Street analysts indicates a potential upside of 86% in Akoya (AKYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 12/27/2023
|
Akoya Biosciences, Inc. (AKYA) Q3 2023 Earnings Call Transcript
- Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Priyam Shah - Head of Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants Edmund Tu - Morgan Stanley Kyle Mikson - Canaccord Genuity Timothy Chiang - Capital One Mason Carrico - Stephens Inc. Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Akoya Biosciences Incorporated Third Quarter 2023 Earnings Conference Call.
- 11/11/2023
|
Akoya to Participate at Three Upcoming Investor Conferences
- MARLBOROUGH, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.
- 11/02/2023
|
Akoya Biosciences, Inc. (AKYA) Q2 2023 Earnings Call Transcript
- Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Priyam Shah - IR Brian McKelligon - CEO John Ek - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Lucas Baranowski - UBS Rachel Vatnsdal - JPMorgan Chase Mark Massaro - BTIG Edmund Tu - Morgan Stanley Tim Chiang - Capital One David Westenberg - Piper Sandler Mason Carrico - Stephens Inc. Operator Good day and welcome to the Akoya Biosciences Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 08/07/2023
|
Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates
- Akoya Biosciences (AKYA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.47 per share a year ago.
- 08/07/2023
|
Akoya to Participate at Three Upcoming Investor Conferences
- MARLBOROUGH, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.
- 07/26/2023
|
Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023
- MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2023 after the market close on Monday, August 7th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 07/12/2023
|
Why Shares of Akoya Biosciences Jumped on Tuesday
- Akoya Biosciences makes single-cell imaging solutions to aid in phenotyping cells. The company is not profitable.
- 06/13/2023
|
Akoya to Participate at Two Upcoming Investor Conferences
- MARLBOROUGH, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in two upcoming investor conferences.
- 06/12/2023
|
Akoya Biosciences shares fall 10% on executive exits, stock offering
- Shares of Akoya Biosciences AKYA, -2.46% on Wednesday dropped 10% to $5.00 in after-hours trading after the company said it fired its chief medical officer and chief people officer as part of a cost-cutting plan.
- 06/07/2023
|
Akoya Biosciences, Inc. (AKYA) Q1 2023 Earnings Call Transcript
- Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Priyam Shah - Investor Relations Brian McKelligon - Chief Executive Officer John Ek - Chief Financial Officer Conference Call Participants Tim Chiang - Capital One Mason Carrico - Stephens Inc Ruizhi Qin - JPMorgan Vivian Bais - BTIG Kyle Mikson - Canaccord Genuity David Westenberg - Piper Sandler Lucas Baranowski - UBS Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences First Quarter 2023 Earnings Conference Call.
- 05/09/2023
|
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates
- Akoya Biosciences (AKYA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.44 per share a year ago.
- 05/08/2023
|
Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023
- MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 04/06/2023
|
Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
- Les Funtleyder, portfolio manager for E Squared Capital Management, joins 'The Exchange' to discuss big cap pharma's Q1 performance, the dollar weakness contributing to biotech gains, and investment opportunities in the pharma space.
- 03/30/2023
|
Akoya Biosciences, Inc. (AKYA) Q4 2022 Earnings Call Transcript
- Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Priyam Shah - Head, Investor Relations Brian McKelligon - Chief Executive Officer Joe Driscoll - Chief Financial Officer Conference Call Participants John Sourbeer - UBS Kyle Mikson - Canaccord Mason Carrico - Stephens Tejas Savant - Morgan Stanley Mark Massaro - BTIG David Westenberg - Piper Sandler Tim Chiang - Capital One Operator Thank you for standing by. And welcome to the Akoya Biosciences Fourth Quarter 2022 Earnings Conference Call.
- 03/07/2023
|
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
- Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/06/2023
|
Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences
- MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Monday, March 6th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 02/06/2023
|
Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting
- Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company's multiomics solution Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company's multiomics solution
- 02/01/2023
|
Akoya Bioscience: Something Special For Investing In A Spatial Bioscience Company
- I will provide readers the basics of what a spatial biotech offers. A key catalyst should drive the future of this bioscience company.
- 01/26/2023
|
Akoya Biosciences, Inc. (AKYA) Q3 2022 Earnings Call Transcript
- Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Priyam Shah - Senior Director, Investor Relations Brian McKelligon - Chief Executive Officer Joseph Driscoll - Chief Financial Officer Conference Call Participants Mason Carrico - Stephens Mark Massaro - BTIG Neil Vibhakar - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2022 Earnings Conference Call.
- 11/07/2022
|
Akoya Biosciences (AKYA) Reports Q3 Loss, Tops Revenue Estimates
- Akoya (AKYA) delivered earnings and revenue surprises of -17.50% and 5.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/07/2022
|
Akoya to Participate at Three Upcoming Investor Conferences
- MARLBOROUGH, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in three upcoming investor conferences.
- 11/03/2022
|
Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022
- MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 10/11/2022
|
Akoya to Participate at Four Upcoming Investor Conferences
- MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming investor conferences.
- 08/31/2022
|
Title: Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q2 2022 Results - Earnings Call Transcript
- Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Priyam Shah - Head of IR Brian McKelligon - CEO Joseph Driscoll - CFO Conference Call Participants Neil Vibhakar - Morgan Stanley Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG David Westenberg - Piper Sandler Operator Thank you for standing by, and welcome to the Akoya Biosciences Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.
- 08/08/2022
|
Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates
- Akoya (AKYA) delivered earnings and revenue surprises of -38.24% and 5.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
Akoya to Participate at Two Upcoming Investor Conferences
- MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in two upcoming investor conferences.
- 07/27/2022
|
Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022
- MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2022 after the market close on Monday, August 8th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 07/12/2022
|
Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q1 2022 Results - Earnings Call Transcript
- Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Priyam Shah - Head of IR Brian McKelligon - CEO Joe Driscoll - CFO Conference Call Participants Dave Westenberg - Piper Sandler Edmund Tu - Morgan Stanley Operator Welcome to the Akoya Biosciences First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded.
- 05/08/2022
|
Akoya to Participate at Three Upcoming Investor Conferences
- MARLBOROUGH, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in three upcoming investor conferences.
- 05/03/2022
|
Akoya to Report First Quarter 2022 Financial Results on May 5th, 2022
- MARLBOROUGH, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 04/14/2022
|
New Strong Sell Stocks for April 11th
- DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on April 11, 2022.
- 04/11/2022
|
New Strong Sell Stocks for April 1st
- AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.
- 04/01/2022
|
New Strong Sell Stocks for March 17th
- DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on March 17, 2022.
- 03/17/2022
|
Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q4 2021 Results - Earnings Call Transcript
- Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q4 2021 Results - Earnings Call Transcript
- 03/14/2022
|
Akoya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14th, 2022 and Present at the Cowen Annual Health Care Conference on March 8th, 2022
- MARLBOROUGH, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Monday, March 14th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 02/22/2022
|
Is a Surprise Coming for Akoya Biosciences (AKYA) This Earnings Season?
- Akoya Biosciences (AKYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/18/2022
|
Akoya Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- MARLBOROUGH, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
- 02/03/2022
|
Which Stocks To Buy Now? 4 Biotech Stocks To Know
- These biotech stocks could be worth watching in 2022.
- 01/07/2022
|
Akoya Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
- MARLBOROUGH, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the 40th Annual J.P. Morgan Healthcare Conference.
- 01/04/2022
|
Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q3 2021 Earnings Call Transcript
- Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q3 2021 Earnings Call Transcript
- 11/08/2021
|
Akoya Biosciences to Present Data at SITC 2021 Highlighting Novel Spatial Biology Applications
- Presentations by the company and customers will offer insights on how spatial phenotypic signatures can accelerate immuno-oncology biomarker development Presentations by the company and customers will offer insights on how spatial phenotypic signatures can accelerate immuno-oncology biomarker development
- 11/04/2021
|
Akoya to Participate at Two Upcoming Investor Conferences in November
- MARLBOROUGH, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in two upcoming investor conferences.
- 11/03/2021
|
Akoya to Report Third Quarter 2021 Financial Results on November 8th, 2021
- MARLBOROUGH, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2021 after the market close on Monday, November 8th, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 10/19/2021
|
Akoya Biosciences Appoints Diagnostics Industry Pioneer Myla Lai-Goldman, MD, to its Board of Directors
- MARLBOROUGH, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Myla Lai-Goldman, MD, a true pioneer and leader in the diagnostic industry, to its board of directors.
- 09/22/2021
|
Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
- MARLBOROUGH, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Morgan Stanley 19th Annual Global Healthcare Conference.
- 08/31/2021
|
Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q2 2021 Results - Earnings Call Transcript
- Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
Akoya Reports 53% Revenue Growth in the Second Quarter of 2021
- MARLBOROUGH, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2021.
- 08/10/2021
|
Akoya Biosciences to Present at the Canaccord 41st Annual Growth Conference
- MARLBOROUGH, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Canaccord 41st Annual Growth Conference.
- 08/03/2021
|
Akoya to Report Second Quarter 2021 Financial Results on August 10, 2021
- MARLBOROUGH, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2021 after the market close on Tuesday, August 10, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 07/20/2021
|
Akoya Announces Publication of the MITRE Study, the First Multi-Institutional Analytical Demonstration of a Spatial Biology Workflow, in the Journal for ImmunoTherapy of Cancer
- Results from the study provide evidence of standardization of an automated spatial biology workflow, based on the company's Phenoptics™ multiplex immunofluorescence (mIF) platform, for clinical and translational research Results from the study provide evidence of standardization of an automated spatial biology workflow, based on the company's Phenoptics™ multiplex immunofluorescence (mIF) platform, for clinical and translational research
- 07/19/2021
|
CrestOptics Selected by Akoya Biosciences for Spatial Biology Collaboration
- ROME, Italy--(BUSINESS WIRE)--CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, today announced that it has been selected by Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, as a premier microscope provider to jointly develop new spatial biology and spatial phenotyping applications. CrestOptics has been invited to the partnership among other leading companies in the field of imagi
- 06/29/2021
|
Akoya to Partner with Nikon, CrestOptics and Andor to Enable New Spatial Biology Applications through the Imaging Innovators (I2) Network
- Company plans to work with multiple microscope partners to broaden access to the CODEX® solution for single-cell, multiplexed imaging Company plans to work with multiple microscope partners to broaden access to the CODEX® solution for single-cell, multiplexed imaging
- 06/29/2021
|
Akoya Biosciences Appoints Diagnostics Industry Leader Scott Mendel to its Board of Directors
- MARLBOROUGH, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced the appointment of diagnostics industry leader Scott Mendel to its board of directors.
- 06/25/2021
|
Akoya to Help Support Leading Philanthropic Organization with Spatial Phenotyping Capabilities
- CODEX's single-cell, multiplex imaging capabilities to be included in Chan Zuckerberg Initiative grantee toolkit to help fuel the next wave of biological discoveries CODEX's single-cell, multiplex imaging capabilities to be included in Chan Zuckerberg Initiative grantee toolkit to help fuel the next wave of biological discoveries
- 06/15/2021
|
Akoya Announces Publication of New Immunotherapy Biomarker Signature in Science, Leveraging Principles of Astronomy and Pathology
- Investigators at Johns Hopkins University (JHU) used AstroPath to identify and validate biomarkers for accurate prediction of long-term response to immune checkpoint inhibitors in advanced melanoma
- 06/10/2021
|
Akoya Set to Join Russell 3000® Index
- MARLBOROUGH, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021.
- 06/09/2021
|
Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology
- Partnership aims to leverage spatial biology data, generated on Akoya's Phenoptics™ platform, to inform and guide drug development programs Partnership aims to leverage spatial biology data, generated on Akoya's Phenoptics™ platform, to inform and guide drug development programs
- 06/04/2021
|
Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications
- Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials
- 06/02/2021
|
Akoya Reports First Quarter 2021 Financial Results and Issues Full Year 2021 Guidance
- MARLBOROUGH, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2021.
- 05/18/2021
|
Akoya and ZEISS to Co-Market Innovative CODEX® Spatial Biology Workflow
- The partnership brings together one of the world's premier microscopy vendors and Akoya's high-parameter CODEX® System for advancing the emerging field of spatial phenotyping and discovery The partnership brings together one of the world's premier microscopy vendors and Akoya's high-parameter CODEX® System for advancing the emerging field of spatial phenotyping and discovery
- 05/17/2021
|
Akoya to Report First Quarter 2021 Financial Results on May 18, 2021
- MARLBOROUGH, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 05/12/2021
|
Akoya Biosciences Begins Accepting Applications for First-of-its-Kind Imaging Innovators (I²) Network
- Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system's open, accessible interface Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system's open, accessible interface
- 05/11/2021
|
DLA Piper advises Akoya Biosciences in its US$151 million initial public offering
- NEW YORK, May 3, 2021 /PRNewswire/ -- DLA Piper represented Akoya Biosciences, Inc. (Nasdaq: AKYA) in its recent initial public offering of 7,567,000 shares of its common stock at a price of $20 per share, including the exercise of the underwriters' option to purchase 987,000 shares of common stock, less underwriting discounts and commissions. Akoya offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response.
- 05/03/2021
|
Akoya Biosciences Announces Pricing of Initial Public Offering
- MARLBOROUGH, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its initial public offering of 6,580,000 shares of its common stock at a price of $20.00 per share, for gross proceeds of $131.6 million, before underwriting discounts and commissions and offering expenses payable by Akoya. Akoya has also granted the underwriters a 30-day option to purchase up to an additional 987,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Akoya. The shares are expected to begin trading on the Nasdaq Global Select Market on April 16, 2021 under the ticker symbol “AKYA.” The offering is expected to close on April 20, 2021, subject to the satisfaction of customary closing conditions.
- 04/15/2021
|
